Stay up to date on NKMax America’s company news and announcements.

Press Releases

Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy

NKMax America Receives FDA Clearance to Amend its Current Phase I Monotherapy Trial to Include an Additional New Cohort of SNK01 + Checkpoint Inhibitor in Refractory Solid Tumors.

NKMax America Receives FDA Clearance of IND for Phase I/2a Trial of their Natural Killer Cell Therapy (SNK01) in Combination with Trastuzumab or Cetuximab for the Treatment of Advanced/Metastatic HER2- or EGFR- Expressing Cancers

Subscribe to NKMax News Updates

* indicates required

NKMax Events

Check back soon for upcoming events!

NKMax on Social Media

Follow NKMax on social media to keep up-to-date on the latest company news and the science of Natural Killer cells!